The U.S. Food and Drug Administration is “almost certain) to require clinical data in order for companies to demonstrate interchangeability between a biosimilar and its reference product, thought the question of how much data will be required is major factor in determining how quickly the U.S. biosimilars market will take off, according to a new report from the law firm Goodwin Proctor.